Imperial College London
Portrait Picture

DrLeorRoseman

Faculty of Medicine, Department of Brain Sciences

Honorary Senior Lecturer
 
 
 
//

Contact

 

leor.roseman13

 
 
//

Location

 

Commonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Carhart-Harris:2017:10.1038/s41598-017-13282-7,
author = {Carhart-Harris, RL and Roseman, L and Bolstridge, M and Demetriou, L and Pannekoek, JN and Wall, MB and Tanner, M and Kaelen, M and McGonigle, J and Murphy, K and Leech, R and Curran, HV and Nutt, DJ},
doi = {10.1038/s41598-017-13282-7},
journal = {Scientific Reports},
title = {Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms},
url = {http://dx.doi.org/10.1038/s41598-017-13282-7},
volume = {7},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Psilocybin with psychological support is showing promise as a treatment model in psychiatry but its therapeutic mechanisms are poorly understood. Here, cerebral blood flow (CBF) and blood oxygen-level dependent (BOLD) resting-state functional connectivity (RSFC) were measured with functional magnetic resonance imaging (fMRI) before and after treatment with psilocybin (serotonin agonist) for treatment-resistant depression (TRD). Quality pre and post treatment fMRI data were collected from 16 of 19 patients. Decreased depressive symptoms were observed in all 19 patients at 1-week post-treatment and 47% met criteria for response at 5 weeks. Whole-brain analyses revealed post-treatment decreases in CBF in the temporal cortex, including the amygdala. Decreased amygdala CBF correlated with reduced depressive symptoms. Focusing on a priori selected circuitry for RSFC analyses, increased RSFC was observed within the default-mode network (DMN) post-treatment. Increased ventromedial prefrontal cortex-bilateral inferior lateral parietal cortex RSFC was predictive of treatment response at 5-weeks, as was decreased parahippocampal-prefrontal cortex RSFC. These data fill an important knowledge gap regarding the post-treatment brain effects of psilocybin, and are the first in depressed patients. The post-treatment brain changes are different to previously observed acute effects of psilocybin and other ‘psychedelics’ yet were related to clinical outcomes. A ‘reset’ therapeutic mechanism is proposed.
AU  - Carhart-Harris,RL
AU  - Roseman,L
AU  - Bolstridge,M
AU  - Demetriou,L
AU  - Pannekoek,JN
AU  - Wall,MB
AU  - Tanner,M
AU  - Kaelen,M
AU  - McGonigle,J
AU  - Murphy,K
AU  - Leech,R
AU  - Curran,HV
AU  - Nutt,DJ
DO  - 10.1038/s41598-017-13282-7
PY  - 2017///
SN  - 2045-2322
TI  - Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
T2  - Scientific Reports
UR  - http://dx.doi.org/10.1038/s41598-017-13282-7
UR  - http://hdl.handle.net/10044/1/52018
VL  - 7
ER  -
Download